British warnings on SSRIs questioned [1]

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 43, Issue 4, 2004, Pages 379-380

  Brent, David A ^a   Birmaher, Boris ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

AUTOMUTILATION; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; HUMAN; LETTER; MONITORING; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; SUICIDE ATTEMPT; ADOLESCENT; CHILD; DRUG CONTROL; STATISTICS; SUICIDE; UNITED KINGDOM;

ADOLESCENT; CHILD; DRUG AND NARCOTIC CONTROL; GREAT BRITAIN; HUMANS; SEROTONIN UPTAKE INHIBITORS; SUICIDE;

EID: 2942718951     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.chi.0000120018.48166.57     Document Type: Letter

References (1)

1. Wagner KD, Ambrosini P, Rynn M et al. (2003), Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 290:1033-1041